Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 494-502

  Allen, Edwin H A ^a,b   Atkinson, Sarah D ^a,b   Liao, Haihui ^b   Moore, Jonathan E ^a   Leslie Pedrioli, Deena M ^b   Smith, Frances J D ^b   McLean, William H Irwin ^b   Moore, C B Tara ^a,b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKERATIN 12; HYBRID PROTEIN; LUCIFERASE; MESSENGER RNA; PLASMID DNA; SMALL INTERFERING RNA;

ALLELE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; FLUORESCENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IMMUNOBLOTTING; MEESMANN CORNEAL DYSTROPHY; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VISUAL STIMULATION; WESTERN BLOTTING;

ALLELES; CELL CULTURE TECHNIQUES; CORNEAL DYSTROPHY, JUVENILE EPITHELIAL OF MEESMANN; DNA; EXONS; GENE SILENCING; HUMANS; KERATIN-12; MUTANT PROTEINS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84874741259     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10528     Document Type: Article

References (44)

1. Meesmann A. Über eine bisher nicht beschriebene dominant vererbte Dystrophia epithelialis corneae. Ber Zusammenkunft Dtsch Ophthalmol Ges. 1938;52:154-158.
2. Irvine AD, McLean WHI. Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br J Dermatol. 1999;140:815-828.
3. Liao H, Irvine AD, Macewen CJ, et al. Development of allelespecific therapeutic siRNA in Meesmann epithelial corneal dystrophy. PloS One. 2011;6:e28582.
4. Chiou AG, Florakis GJ, Copeland RL, Williams VA, McCormick SA, Chiesa R. Recurrent Meesmann's corneal epithelial dystrophy after penetrating keratoplasty. Cornea. 1998;17: 566-570.
5. Goldberg A, Schlotzer-Schrehardt U, Seiler T. Unilateral Meesmann's dystrophy. Int Ophthalmol. 1997;21:117-120.
6. Irvine AD, Coleman CM, Moore JE, et al. A novel mutation in KRT12 associated with Meesmann's epithelial corneal dystrophy. Br J Ophthalmol. 2002;86:729-732.
7. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nature Rev Genet. 2011;12: 329-340.
8. McLean WH, Moore CB. Keratin disorders: from gene to therapy. Hum Mol Genet. 2011;20:R189-R197.
9. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature. 1998;391: 806-811.
10. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2:711-719.
11. Hickerson RP, Smith FJD, Reeves RE, et al. Single-nucleotidespecific siRNA targeting in a dominant-negative skin model. J Invest Dermatol. 2008;128:594-605.
12. Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: an update on delivery. Current Opin Mol Ther. 2008;10:158-167.
13. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell. 2006;126:231-235.
14. Haussecker D. The business of RNAi therapeutics. Human Gene Ther. 2008;19:451-462.
15. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nature Rev Drug Discov. 2009;8:129-138.
16. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107:8800-8805.
17. Smith FJ, Hickerson RP, Sayers JM, et al. Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol. 2008;128:50-58.
18. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-1070.
19. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443-453.
20. Kaspar RL. Challenges in developing therapies for rare diseases including pachyonychia congenita. J Investig Dermatol Symp Proc. 2005;10:62-66.
21. Lewin AS, Glazer PM, Milstone LM. Gene therapy for autosomal dominant disorders of keratin. J Investig Dermatol Symp Proc. 2005;10:47-61.
22. Corden LD, Swensson O, Swensson B, et al. Molecular genetics of Meesmann's corneal dystrophy: ancestral and novel mutations in keratin 12 (K12) and complete sequence of the human KRT12 gene. Exp Eye Res. 2000;70:41-49.
23. Irvine AD, Corden LD, Swensson O, et al. Mutations in corneaspecific keratins K3 or K12 cause Meesmann's corneal dystrophy. Nat Genet. 1997;16:184-187.
24. Kleinman ME, Kaneko H, Cho WG, et al. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther. 2012;20:101-108.
25. Notara M, Daniels JT. Characterisation and functional features of a spontaneously immortalised human corneal epithelial cell line with progenitor-like characteristics. Brain Res Bull. 2010; 81:279-286.
26. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988;106:761-771.
27. Atkinson SD, McGilligan VE, Liao H, et al. Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J Invest Dermatol. 2011;131: 2079-2086.
28. Leslie Pedrioli DM, Fu DJ, Gonzalez-Gonzalez E, et al. Generic and personalized RNAi-based therapeutics for a dominantnegative epidermal fragility disorder. J Invest Dermatol. 2012; 132:1627-1635.
29. Rugg EL. Detection and characterization of keratins by immunocytochemistry and immunoblotting. In: Leigh IM, Lane EB, Watt FM, eds. Keratinocyte Methods. Cambridge, UK: Cambridge University Press; 1994;127-148.
30. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173-178.
31. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001;20: 6877-6888.
32. Hickerson RP, Leachman SA, Pho LN, et al. Development of quantitative molecular clinical end points for siRNA clinical trials. J Invest Dermatol. 2011;131:1029-1036.
33. Rugg EL, McLean WH, Lane EB, et al. A functional "knockout" of human keratin 14. Genes Dev. 1994;8:2563-2573.
34. Cao T, Longley MA, Wang XJ, Roop DR. An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy. J Cell Biol. 2001;152:651-656.
35. Leachman SA, Hickerson RP, Schwartz ME, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010;18:442-446.
36. Szeverenyi I, Cassidy AJ, Chung CW, et al. The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat. 2008;29:351-360.
37. Boutboul S, Black GC, Moore JE, et al. A subset of patients with epithelial basement membrane corneal dystrophy have mutations in TGFBI/BIGH3. Hum Mutat. 2006;27:553-557.
38. Munier FL, Frueh BE, Othenin-Girard P, et al. BIGH3 mutation spectrum in corneal dystrophies. Invest Ophthalmol Vis Sci. 2002;43:949-954.
39. Korvatska E, Henry H, Mashima Y, et al. Amyloid and nonamyloid forms of 5q31-linked corneal dystrophy resulting from kerato-epithelin mutations at Arg-124 are associated with abnormal turnover of the protein. J Biol Chem. 2000;275: 11465-11469.
40. Ueta M, Hamuro J, Kiyono H, Kinoshita S. Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res Commun. 2005;331:285-294.
41. Li J, Shen J, Beuerman RW. Expression of toll-like receptors in human limbal and conjunctival epithelial cells. Mol Vis. 2007; 13:813-822.
42. Hao J, Li SK, Kao WW, Liu CY. Gene delivery to cornea. Brain Res Bull. 2010;81:256-261.
43. Leachman SA, Hickerson RP, Hull PR, et al. Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci. 2008;51:151-157.
44. Hanna C, O'Brien JE. Cell production and migration in the epithelial layer of the cornea. Arch Ophthalmol. 1960;64:536-539.